AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Enliven Therapeutics to Present Data at SOHO 2025 Annual Meeting
ByAinvest
Monday, Aug 25, 2025 6:25 pm ET1min read
Enliven Therapeutics will present data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting. The data, previously presented at the European Hematology Association (EHA) 2025 Congress, will be presented in both an oral and a poster session. Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for oncology.
Enliven Therapeutics, Inc. (Nasdaq: ELVN) will present data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting. The trial focuses on ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated Chronic Myeloid Leukemia (CML). The data will be presented in both oral and poster formats by Dr. Michael J. Mauro on September 3-4, 2025, at the George R. Brown Convention Center in Houston. This presentation is an encore of previously presented data at the European Hematology Association (EHA) 2025 Congress [1][2].The oral session is titled "Session V: Chronic Myeloid Leukemia" and will be presented on Thursday, September 4, from 11:40 a.m. to 11:50 a.m. CDT. The poster session will take place on Wednesday, September 3, at 6:25 p.m. CDT, located at Hall B3, Level 3, with poster number CML-575 [2].
Enliven Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, focused on the discovery and development of small molecule therapeutics. The company aims to address unmet needs in oncology with a precision approach that improves survival and enhances overall well-being. The data presentation at SOHO 2025 is expected to provide insights into the efficacy and safety of ELVN-001 in treating CML [1][2].
References:
[1] https://www.stocktitan.net/news/ELVN/enliven-therapeutics-announces-oral-and-poster-presentations-at-the-at51d7emlwqd.html
[2] https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-oral-and-poster-presentations-at-the-society-of-hematologic-oncology-soho-2025-annual-meeting-302538061.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet